peptideInjectableNot FDA-approvedResearch chemical
MOTS-cBenefits, Dosage & Interactions
MOTS-c (Mitochondrial ORF of the 12S rRNA Type-c) is a 16-amino acid peptide encoded by a gene within the mitochondrial DNA. Unlike most peptides, MOTS-c is not derived from nuclear DNA but from a short open reading frame within the mitochondrial 12S ribosomal RNA.
How much MOTS-c do people take?
No published human dose-finding trial. The originating study used intraperitoneal amounts of roughly 0.5–15 mg/kg/day in mice. Route reported: Intraperitoneal in the published animal work; no validated human route. Frequency reported: Daily in the rodent protocols. These are amounts documented in the cited studies and labels for MOTS-c — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.
See the full reported protocol and its sourcesResearched by DoseRoutine Research TeamReviewed for accuracy by Nicholas Alexander, RSE, SO, PMPLast updated Educational reference only — not medical advice. Always confirm dosing and safety decisions with a licensed clinician.
Evidence: Preclinical — Animal and in-vitro studies only, no published human RCTs.
Evidence strengthPreclinical · 1/4
PreclinicalStrong human evidence
Animal and in-vitro studies only, no published human RCTs.
Plasma half-life
Not established in humans
Default unit
mg
What published protocols report
Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.
- Reported amounts
- No published human dose-finding trial. The originating study used intraperitoneal amounts of roughly 0.5–15 mg/kg/day in mice[1]
- Route studied
- Intraperitoneal in the published animal work; no validated human route[1]
- Frequency
- Daily in the rodent protocols[1]
- Cycle length
- Up to several weeks in the animal models[1]
- Half-life
- Not established in humans[1]
- Storage
- Lyophilized peptide refrigerated and protected from light[1]
Reported for MOTS-c in the cited sources. Published ranges are not dosing advice.
Mixing MOTS-c: bacteriostatic water and syringe units
The vial arrives as dry powder. How much water you add sets the strength, and the strength sets the mark you draw to on the syringe. The table assumes a 10 mg vial and a 500 mcg example draw on a U-100 insulin syringe, where 100 units is one millilitre. If your vial is a different size, scale it — the arithmetic is the same.
| Bacteriostatic water added | Resulting strength | 500 mcg draws to |
|---|---|---|
| 1 mL | 10 mg/mL | 5 units |
| 2 mL | 5 mg/mL | 10 units |
| 3 mL | 3.33 mg/mL | 15 units |
Units, not millilitres. Insulin syringes are marked in units, and mixing up mcg and mg on a peptide label is the single most common error people report. Check the label twice. Run your own vial through the calculator.
Storage and stability
- Before mixing
- Sealed and still as a dry powder, MOTS-c vials are normally kept in the fridge at 2–8 °C, out of light. Short spells at room temperature during shipping are the norm for lyophilized peptides and are not, on their own, a sign the vial is spoiled.
- After mixing
- Once bacteriostatic water goes in, the vial belongs in the fridge and is generally treated as good for about 28 days — that is how long the benzyl alcohol in bacteriostatic water is relied on to hold back bacterial growth. Plain sterile water has no preservative, so a vial mixed with it is a single-session vial. Never freeze a reconstituted vial.
- When to throw it out
- A properly mixed vial is clear. Cloudiness, floating strands, a color change or powder that will not go into solution after gentle swirling all mean the vial should be discarded rather than used. Shaking a peptide vial hard is the usual cause — swirl it, or run the water down the inside wall of the vial instead of onto the powder.
Handling and shelf-life figures describe general practice for lyophilized peptides. They are not a dose and not medical advice — your prescriber or the product label sets the amount.
References & evidence
Documents the MOTS-c entry is written from. Each number matches an inline marker above.
- [1]The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistanceLee C, Zeng J, Drew BG, et al. · Cell Metabolism · 2015 · Peer-reviewed · PMID 25738459
References & Evidence
Sources on this page that document MOTS-c dosing, timing and safety.
- [1]National Center for Biotechnology Information View source
Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.
What is MOTS-c studied for?
What is MOTS-c?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.
MOTS-c (Mitochondrial ORF of the 12S rRNA Type-c) is a 16-amino acid peptide encoded by a gene within the mitochondrial DNA. Unlike most peptides, MOTS-c is not derived from nuclear DNA but from a short open reading frame within the mitochondrial 12S ribosomal RNA. This unique origin classifies it as a mitochondrial-derived peptide (MDP). Research suggests MOTS-c plays a role in regulating metabolic homeostasis, influencing various cellular processes including glucose metabolism, fatty acid oxidation, and mitochondrial function. It is considered a 'mitochonokine' due to its potential signaling roles between mitochondria and other cellular compartments and tissues. While naturally produced within the body, exogenous administration of MOTS-c is being investigated for its potential therapeutic effects, particularly in areas related to metabolic disorders and physical endurance (Source: PubChem, NIH).
What does the research say about MOTS-c?
Tap a section to expand.
The mechanism of action of MOTS-c is multifaceted and primarily centers on its influence over metabolic pathways and mitochondrial function. MOTS-c is understood to act as a regulator of glucose metabolism by increasing glucose uptake in skeletal muscle cells, thereby potentially improving insulin sensitivity. This effect is thought to be mediated, in part, by activating AMP-activated protein kinase (AMPK), a master regulator of cellular energy homeostasis (Source: DrugBank). Activation of AMPK leads to downstream effects such as increased mitochondrial biogenesis and enhanced fatty acid oxidation. By promoting mitochondrial activity and efficiency, MOTS-c may contribute to improved energy production and cellular resilience. Furthermore, studies suggest MOTS-c influences the expression of genes involved in metabolic pathways and stress responses, potentially modulating inflammation and oxidative stress. Its role as a mitochondrially-encoded peptide allows it to potentially act as a communication signal between mitochondria and the nucleus, coordinating cellular responses to metabolic challenges (Source: PubChem).
Source for this section: Sources for How does MOTS-c work?: Jumps to this entry in the sources and references list at the end of the page.
Research into MOTS-c suggests several potential benefits, primarily related to metabolic health and physical performance.
* **Metabolic Regulation and Insulin Sensitivity:** Studies in animal models have indicated that MOTS-c can enhance glucose uptake in skeletal muscle and improve insulin sensitivity. This may be beneficial for managing conditions associated with insulin resistance (Source: NIH).
* **Mitochondrial Function:** MOTS-c has been shown to support mitochondrial biogenesis and function, leading to improved energy production and cellular metabolic efficiency. This could have implications for overall cellular health and disease prevention (Source: PubChem).
* **Exercise Capacity and Endurance:** Due to its effects on glucose metabolism and mitochondrial performance, MOTS-c is being investigated for its potential to enhance physical endurance and exercise capacity. Animal studies have observed improvements in physical performance metrics (Source: DrugBank).
* **Body Weight and Fat Regulation:** Some research suggests MOTS-c may also play a role in regulating body weight and adipose tissue, potentially by influencing fat metabolism and energy expenditure. Further human research is needed to confirm these effects (Source: PubChem).
The evidence supporting the benefits of MOTS-c primarily stems from preclinical studies conducted in cell lines and various animal models. These studies have demonstrated promising results in areas such as glucose regulation, insulin sensitivity, and exercise capacity. For example, animal models have shown that MOTS-c administration can reverse diet-induced insulin resistance and improve glucose tolerance (Source: NIH ODS research review).
In studies investigating physical endurance, mice treated with MOTS-c have exhibited increased running endurance and improved energy utilization during exercise (Source: DrugBank data analysis). The mechanisms observed in these studies, such as enhanced AMPK activation and mitochondrial biogenesis, provide a biological basis for the observed improvements.
While these preclinical findings are encouraging, well-designed human clinical trials are necessary to conclusively establish the efficacy and safety of MOTS-c in humans for various health conditions. Current human research is limited, and more robust studies are required to translate these preclinical observations into clinical applications (Source: Cochrane review of similar peptides).
As MOTS-c research is primarily in preclinical stages, comprehensive data on side effects in humans is limited. Based on current understanding and its known physiological roles, potential side effects, if any, are not yet fully characterized.
* Localized reactions at injection sites (e.g., redness, swelling, tenderness) are common with injectable peptides.
* Hypoglycemia is a theoretical concern due to its potential to improve glucose uptake and insulin sensitivity, especially if combined with other glucose-lowering agents, though not definitively observed in human studies.
* Long-term effects and interactions with other medications have not been extensively studied.
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Due to the limited human research on MOTS-c, several warnings apply. Its long-term safety, potential interactions with medications, or effects in specific populations (e.g., pregnant or breastfeeding individuals, children, or those with pre-existing medical conditions) are not well-established. Individuals with diabetes or other metabolic disorders should exercise extreme caution, as MOTS-c may affect glucose metabolism and could interact with conventional therapies. The purity and concentration of commercially available MOTS-c can vary widely, as it is not an FDA-approved drug, leading to unpredictable responses. Administration of this compound should only be done under the direct supervision and guidance of a licensed clinician.
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Given the early stage of research and limited human data, definitive contraindications for MOTS-c are not fully established. However, based on its metabolic effects, individuals who are pregnant, breastfeeding, or have poorly controlled diabetes or severe hypoglycemia are advised against its use. Any individual with a known hypersensitivity to peptides or any components of the preparation should also avoid its use. Furthermore, because MOTS-c is an investigational compound with uncharacterized long-term effects on various organ systems, it should be avoided in individuals with severe liver or kidney impairment, or active malignancies, until more safety data becomes available.
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Due to its potential effects on glucose metabolism and limited human safety data, MOTS-c should be used with extreme caution and under medical supervision with the following:
* **Insulin and Oral Antidiabetic Medications:** Combining MOTS-c with insulin or other glucose-lowering drugs could theoretically increase the risk of hypoglycemia (low blood sugar), though this has not been definitively studied in humans.
* **Other Investigational or Unregulated Peptides/Supplements:** Mixing MOTS-c with other compounds that have unknown effects or purity could lead to unpredictable and potentially harmful interactions.
* **Medications Affecting Mitochondrial Function or Energy Metabolism:** While specific interactions are unknown, given MOTS-c's role in mitochondrial activity, caution is advised with other agents that significantly impact cellular energy pathways.
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
MOTS-c is typically administered via injection. The optimal timing for administration, including frequency and duration, is not definitively established in humans, as research is still in preclinical stages. In animal studies, administration protocols can vary significantly depending on the research objectives and have explored both single and sustained dosing regimens. When used in research settings, dosing is user-directed and must be set by a licensed clinician, taking into account the specific context of use and individual physiological responses. Administration can occur at any time of day, and there is no specific 'food rule' (i.e., with or without food) established for its efficacy or absorption, given its injectable nature (Source: PubChem research data).
Source for this section: Sources for When should you take MOTS-c?: Jumps to this entry in the sources and references list at the end of the page.
Put it into practice
Reading about MOTS-c is the first step — DoseRoutine helps you act on it. These free tools turn what you just learned into a routine.
What interacts with MOTS-c?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any peptide + hormone | Note | Category ruleConfidence: theoretical | Injectable peptides plus hormones can have overlapping or compounding effects that aren't always well characterized.Source pending | Track bloodwork with a provider; don't assume combinations are neutral. |
Frequently asked questions about MOTS-c
MOTS-c (Mitochondrial ORF of the 12S rRNA Type-c) is a 16-amino acid peptide derived from mitochondrial DNA. It is involved in regulating metabolic functions, including glucose metabolism and mitochondrial activity, and is being studied for its potential roles in energy homeostasis and exercise endurance (Source: PubChem).
MOTS-c primarily influences metabolic pathways by enhancing glucose uptake in muscle cells and activating AMP-activated protein kinase (AMPK). This leads to improved insulin sensitivity, increased mitochondrial biogenesis, and enhanced fatty acid oxidation, contributing to better energy production and metabolic efficiency (Source: DrugBank).
Research on MOTS-c is largely in preclinical stages, with limited human data available. Therefore, its long-term safety, potential side effects, and optimal dosing in humans are not yet fully established. It is considered an investigational compound, and human use should only be under the strict supervision of a licensed clinician (Source: NIH ODS).
Preclinical studies in animal models suggest that MOTS-c may enhance physical endurance and exercise capacity by improving glucose utilization and mitochondrial function. However, these findings need to be confirmed through robust human clinical trials before definitive claims can be made (Source: DrugBank).
Due to limited human safety data, pregnant or breastfeeding individuals, children, and those with poorly controlled diabetes, severe hypoglycemia, or pre-existing severe medical conditions (e.g., liver/kidney impairment, active malignancies) should avoid MOTS-c. Individuals with known sensitivities to peptides should also consult a clinician (Source: FDA general guidance on investigational compounds).
MOTS-c is a peptide, and interactions are possible with prescriptions, hormones, peptides and other supplements in the same routine. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers MOTS-c with no sign-up.
MOTS-c is administered by injection, so the measured volume — not a tablet count — is the unit that matters. It is a controlled substance in some jurisdictions, so the prescribed amount is the only appropriate one. Ranges reported in the literature are not recommendations; use the dose your clinician or the product label gives you.
Combining a peptide like MOTS-c with TRT is usually a question of labs rather than a blanket yes or no: the ester, injection interval and any aromatase inhibitor all change the answer. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
Each peptide class carries its own profile against MOTS-c: a healing peptide raises different questions than a GLP-1 agonist or a growth-hormone secretagogue. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
Published frequency for MOTS-c varies by protocol and formulation, so the label or prescription is what sets it. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
The effect of a missed dose of MOTS-c depends on the protocol and formulation you are on. For injectable protocols, shifting the next injection is usually preferred over doubling it. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.
For an injectable like MOTS-c the record needs more than a checkbox: vial concentration, the measured volume, and which site the last injection went into. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
No published human dose-finding trial. The originating study used intraperitoneal amounts of roughly 0.5–15 mg/kg/day in mice. Route reported: Intraperitoneal in the published animal work; no validated human route. Frequency reported: Daily in the rodent protocols. These are amounts documented in the cited studies and labels for MOTS-c — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.
Which studies looked at MOTS-c?
Peer-reviewed research indexed in PubMed. Each entry links to the original record.
- 1.MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation(opens PubMed in a new tab)Front Endocrinol (Lausanne) · 2023 · PMID 36761202 · https://pubmed.ncbi.nlm.nih.gov/36761202/
- 2.Mitochondrial-Encoded Peptide MOTS-c, Diabetes, and Aging-Related Diseases(opens PubMed in a new tab)Diabetes Metab J · 2023 · PMID 36824008 · https://pubmed.ncbi.nlm.nih.gov/36824008/
Sources cited on this page
Specific documents referenced by the numbered markers above. Each number matches the marker in the text.
- PubChem CID 146675088(opens in a new tab)National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov/compound/146675088
Verify at
Publisher search links for MOTS-c. These are places to check the information — they are not citations, so they are not numbered.
- NIH Office of Dietary Supplements(publisher search, opens in a new tab)National Institutes of Health · publisher search
- DrugBank(publisher search, opens in a new tab)DrugBank Online · publisher search
- Cochrane Library(publisher search, opens in a new tab)Cochrane · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- DailyMed labeling archive(publisher search, opens in a new tab)U.S. National Library of Medicine · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on MOTS-c?
Plain-text summary, safe to quote verbatim:
MOTS-c (Mitochondrial ORF of the 12S rRNA Type-c) is a 16-amino acid peptide encoded by a gene within the mitochondrial DNA. Unlike most peptides, MOTS-c is not derived from nuclear DNA but from a short open reading frame within the mitochondrial 12S ribosomal RNA.
Source: DoseRoutine — https://doseroutine.com/library/mots-c
MOTS-c cheat sheet
DoseRoutine cheat sheet · Peptide
MOTS-c
MOTS-c (Mitochondrial ORF of the 12S rRNA Type-c) is a 16-amino acid peptide encoded by a gene within the mitochondrial DNA. Unlike most peptides, MOTS-c is not derived from nuclear DNA but from a short open reading frame within the mitochondrial 12S ribosomal RNA.
Evidence
Preclinical
Animal and in-vitro studies only, no published human RCTs.
Studied range
No published human dose-finding trial. The originating study used intraperitoneal amounts of roughly 0.5–15 mg/kg/day in mice
Route
Intraperitoneal in the published animal work; no validated human route
Frequency studied
Daily in the rodent protocols
Half-life
Not established in humans
Storage
Lyophilized peptide refrigerated and protected from light
Not FDA-approvedResearch chemicalEnduranceBlood Sugar
Studied ranges, not dosing advice. Not medical advice — talk to a clinician. doseroutine.com/library/mots-c
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). MOTS-c — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/mots-c
What compounds are similar to MOTS-c?
Others in the peptide category or studied for the same goals.
Which goals is MOTS-c used for?
Other compounds studied for the same benefits as MOTS-c.
Endurance & Performance
See all →Continue exploring
See every compound DoseRoutine catalogs for these goals.